Reperfusion Injury and Infarct Size: Why Translation has Been Difficult, and How We Move Forward. (PubMed, Curr Cardiol Rep) - Aug 13, 2026 - "Although the PITRI trial showed reduced periprocedural platelet reactivity with cangrelor there was no reduction in infarct size or microvascular obstruction (MVO), exemplifying proximal target engagement without affecting imaging surrogates...The path forward is to align patient selection, phenotype-specific endpoints, and adaptive trial architecture, and to test mechanical interventions together with pharmacological adjuncts rather than in isolation. When these elements are aligned - as the SSO₂ programme arc suggests - cardioprotection in STEMI may yet deliver clinically meaningful benefit."
Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Reperfusion Injury
|
|
Derek J Hausenloy; Heerajnarain Bulluck
|